A5054519943- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Advanced Breast Cancer Therapies
- Cancer Cells and Metastasis
- Protease and Inhibitor Mechanisms
- Extracellular vesicles in disease
- Cytokine Signaling Pathways and Interactions
- NF-κB Signaling Pathways
- Angiogenesis and VEGF in Cancer
- Cell Adhesion Molecules Research
- Cancer, Lipids, and Metabolism
- Advanced Biosensing Techniques and Applications
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- Brain Metastases and Treatment
- Immunotherapy and Immune Responses
- Curcumin's Biomedical Applications
- BRCA gene mutations in cancer
- Lymphatic System and Diseases
Samsung Medical Center
2013-2024
Sungkyunkwan University
2013-2023
Samsung (South Korea)
2017-2023
Korea Institute for Advanced Study
2020
Chonnam National University
2004-2006
Abstract Breast cancer (BC) in the Asia Pacific regions is enriched younger patients and rapidly rising incidence yet its molecular bases remain poorly characterized. Here we analyze whole exomes transcriptomes of 187 primary tumors from a Korean BC cohort (SMC) pre-menopausal perform systematic comparison with primarily Caucasian post-menopausal (TCGA). SMC harbors higher proportions HER2+ Luminal B subtypes, lower proportion A decreased ESR1 expression compared to TCGA. We also observe...
Abstract Exosomes in blood play an important role cell-to-cell signaling and are a novel source of biomarkers for the diagnosis prognosis diseases. Recently, evidence has accumulated that cytokines released from encapsulated exosomes capable eliciting biological effects upon contact with sensitive cells. However, there is currently limited information on exosome isolation methods cytokine research. In this study, we evaluated three their usability, yield, purity, effectiveness subsequent...
// Ji Yun Lee 1, * , Kyunghee Park 2, Sung Hee Lim 1 Hae Su Kim Kwai Han Yoo Ki Sun Jung Haa-Na Song Mineui Hong 3 In-Gu Do TaeJin Ahn 2 Se Kyung 4 Soo Youn Bae Seok Won Jeong Eon Jin Nam Duk-Hwan 5 Hyun 6 Ji-Yeon Young-Hyuck Im Yeon Division of Hematology-Oncology, Department Medicine, Samsung Medical Center, Sungkyunkwan University School Seoul, Korea Genomic Institute, Biological Research Center Companion Diagnostics, Innovative Cancer Medicine Surgery, Molecular Cell Biology, Biomedical...
Abstract The biology of breast cancer brain metastasis (BCBM) is poorly understood. We aimed to explore genes that are implicated in the process primary (BC). NanoString nCounter Analysis covering 252 target was used for comparison gene expression levels between 20 BCs relapsed and 41 BCBM samples. PAM50-based intrinsic subtypes such as HER2-enriched basal-like were clearly over-represented BCBM. A panel 22 found be significantly differentially expressed BC Five these genes, CXCL12 , MMP2...
TP53, the most frequently mutated gene in breast cancer, is more altered HER2-enriched and basal-like cancer. However, no studies have clarified role of TP53 status as a prognostic predictive marker triple-negative cancer (TNBC).We performed p53 immunohistochemistry (IHC), nCounter mRNA expression assay, DNA sequencing to determine relationship between alteration clinical outcomes TNBC patients.Seventy-seven 174 patients were found harbor mutation. Patients with missense mutations showed...
Abstract We investigated gene expression profiles of the NF-κB pathway in patients with triple-negative breast cancer (TNBC) receiving adjuvant chemotherapy to determine prognostic value genes according chemotherapeutic regimen. used nCounter assay measure 11 (NFKB1, NFKB2, RELA, RELB, REL, TP53, FOXC1, TBP, SP1, STAT3 and IRF1 genes) belonging using mRNA extracted from paraffin-embedded tumor tissues 203 diagnosed TNBC. Of patients, 116 were treated a regimen containing doxorubicin. As...
Triple-negative breast cancer (TNBC) is known for aggressive biologic features and poor prognosis. Epidermal growth factor receptor (EGFR) overexpression in TNBC indicates However, there no previous study of the relationship between expression entire human epidermal (HER) family genes patient prognosis TNBC. Accordingly, we investigated profiles HER patients with to determine prognostic value clinical implications expression.We used nCounter assay (NanoString®) measure EGFR, erb-B2 tyrosine...
// Yeon Hee Park 1, 2, * , Hyun-Tae Shin 3, Hae Hyun Jung 2 Yoon-La Choi 3 TaeJin Ahn Kyunghee Aeri Lee 4 In-Gu Do 5 Ji-Yeon Kim Jin Seok 1 Woong-Yang Young-Hyuck Im Division of Hematology-Oncology, Department Medicine, Samsung Medical Center, Sungkyunkwan University School Seoul, Korea Biomedical Research Institute, Genomic Bio and Brain Engineering, Advanced Institute Science Technology, Daejeon, Center Companion Diagnostics, Innovative Cancer Medicine These authors have contributed...
Abstract We investigated the molecular mechanisms underlying statin-induced growth suppression of triple-negative breast cancer (TNBC) that overexpress transcription factor ets proto-oncogene 1(ets-1) and downregulate dual specific protein phosphatase 4(dusp4) expression. examined gene expression BC cell lines using nCounter assay, MTT viability proliferation assay Western blot to evaluate effects simvastatin. Finally, we performed testing in TNBC line-transfected DUSP4 . demonstrated ETS1...
// Ji-Yeon Kim 1, * , Eunjin Lee 2, Kyunghee Park 2 Woong-Yang Hae Hyun Jung 4 Jin Seok Ahn 1 Young-Hyuck Im 3 Yeon Hee 3, Division of Hematology-Oncology, Department Medicine, Samsung Medical Center, Sungkyunkwan University School Seoul, 06351, Korea Genome Institute, Biomedical Research Advanced Institute for Health Sciences and Technology, These authors contributed equally to this work Correspondence to: Park, email: yhparkhmo@skku.edu Keywords: metastatic, breast cancer, TP53, PIK3CA...
Abstract Apocrine carcinoma is a rare breast cancer subtype. As such, the genomic characteristics of apocrine with triple negative immunohistochemical results (TNAC), which has been treated as (TNBC), have not revealed. In this study, we evaluated TNAC compared to TNBC low Ki-67 (LK-TNBC). genetic analysis 73 TNACs and 32 LK-TNBCs, most frequently mutated driver gene in was TP53 (16/56, 28.6%), followed by PIK3CA (9/56, 16.1%), ZNF717 (8/56, 14.3%), PIK3R1 (6/56, 10.71%). Mutational...
Abstract Activated monocyte‐macrophages have been implicated in tumor angiogenesis via their capacity to produce many potent angiogenic factors. However, the mechanisms leading production of these factors macrophages remain be elucidated. In this study, we demonstrated by use a mouse Matrigel implantation model that peritoneal induce angiogenesis. mRNA expression and protein synthesis macrophage‐derived crucial such as IL‐1, TNF‐α, basic fibroblast growth factor, vascular endothelial factor...
In breast cancer (BC), up to 10-20% patients were known have clinical benefit with immune checkpoint inhibitors, and biomarkers are needed for optimal use of this multi-potential therapeutic strategy. Accordingly, we conducted an experiment identify expression genes associated checkpoints that represent potential targets immunotherapy. We performed whole-transcriptome sequencing whole-exome using 37 refractory BC specimens. the pathway gene set analysis, found HER2 previous taxane treatment...
The aim of this study was to investigate candidate genes that might function as biomarkers differentiate triple negative breast cancers (TNBCs) among patients, who received adjuvant chemotherapy after curative surgery. We tested whether the results a NanoString expression assay targeted 250 prospectively selected and used mRNA extracted from formalin‐fixed, paraffin‐embedded would predict distant recurrence in patients with TNBC. levels seven were defined algorithm allocate each patient risk...
We aimed to investigate the impact of genetic alterations on efficacy poziotinib in a phase II clinical trial patients with heavily treated HER2-positive metastatic breast cancer (BC). performed targeted ultra-deep sequencing customized gene panel and RNA expression assay using BC specimens. Of 106 patients, biomarker data were available for 85. Copy number (CN) amplifications HER2 observed 72 (85%), CN >8 50 (59%). Single nucleotide variants (SNVs) found 16 (19%). Genetic PIK3CA pathway 40...
Neoadjuvant chemotherapy (NAC) is a standard treatment strategy for patients with locally advanced breast cancer (LABC). However, there are no established predictors of chemosensitivity and survival in LABC who undergo NAC. Many studies have demonstrated that exosomes cytokines important players intercellular communication between tumors their environments, involved resistance. Recently, it was reported can be packaged into exosomes, but whether exosomal serve as biomarkers still unclear. In...
Circulating tumor DNA (ctDNA) correlates with burden and provides early detection of treatment response genetic alterations in breast cancer (BC). In this study, we aimed to identify during the process clonal evolution examine if ctDNA level well indicated clinical neoadjuvant chemotherapy (NAC) BC recurrence. We performed targeted ultra-deep sequencing plasma DNAs, matched germline DNAs from locally advanced patients. Serial were collected at diagnosis, after 1st cycle NAC curative surgery....
We investigated the role of p53 in nuclear factor (NF)‐κB dependent, platelet‐activating (PAF)‐induced vascular endothelial growth (VEGF) expression. Transfected NF‐κB subunits ECV304 cells increased tumor necrosis factor‐α promoter activity, which was completely inhibited by p53. p53RE subunits, indicating that cross‐regulation occurs between and PAF‐induced increase VEGF expression correlated with decreased activity. These data suggest NF‐κB‐dependency is due to reciprocally regulated
Abstract Background: Triple-negative breast cancer (TNBC) have had significantly worse survival outcome compared to other BC subtypes even though treatment strategies of TNBC been advanced. The advent immune checkpoint inhibitors (ICIs), especially pembrolizumab, a PD-1 inhibitor, has started revolutionize treatment, showing encouraging effects in improving outcomes regardless settings. In neoadjuvant setting, pembrolizumab with cytotoxic chemotherapy achieved 13.6 % pathologic complete...